Trading Restenosis for Thrombosis? New Questions about Drug-Eluting Stents
Author:
- 9 November 2006
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (19) , 1949-1952
Abstract
In September, at the World Cardiology Congress in Barcelona, Donald Baim, a cardiologist who is the new chief medical and scientific officer of Boston Scientific, was talking to a reporter when he mentioned disturbing new findings regarding the risk of late thrombosis associated with drug-eluting coronary stents. The revelation fueled a newly ignited controversy. Lauded as a means of preventing restenosis, drug-eluting stents have been implanted in nearly 6 million patients worldwide since they were introduced 3 years ago. The Food and Drug Administration (FDA) responded to the controversy by issuing a statement that drug-eluting stents are “safe and effective . . .Keywords
This publication has 3 references indexed in Scilit:
- ESC guidelines for percutaneous coronary interventions: replyEuropean Heart Journal, 2005
- Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting StentsJAMA, 2005
- ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive SummaryJACC, 2004